Nippon Life Global Investors Americas Inc. Sells 4,460 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Nippon Life Global Investors Americas Inc. decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 9.3% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 43,330 shares of the medical research company’s stock after selling 4,460 shares during the period. Nippon Life Global Investors Americas Inc.’s holdings in IQVIA were worth $8,515,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Synergy Asset Management LLC acquired a new position in shares of IQVIA during the 4th quarter worth about $33,000. GKV Capital Management Co. Inc. acquired a new position in shares of IQVIA during the 4th quarter worth approximately $39,000. Lee Danner & Bass Inc. acquired a new stake in shares of IQVIA in the 4th quarter valued at approximately $44,000. Zions Bancorporation N.A. raised its position in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after acquiring an additional 85 shares in the last quarter. Finally, Versant Capital Management Inc grew its position in shares of IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 93 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Down 1.8 %

Shares of IQVIA stock opened at $141.38 on Tuesday. The firm has a market capitalization of $24.93 billion, a PE ratio of 18.85, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm’s 50 day moving average is $175.30 and its 200 day moving average is $195.79. IQVIA Holdings Inc. has a 1 year low of $135.97 and a 1 year high of $252.88.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Robert W. Baird lowered their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. Citigroup reduced their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Morgan Stanley lifted their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Mizuho reduced their price objective on IQVIA from $242.00 to $210.00 and set an “outperform” rating for the company in a report on Wednesday, April 9th. Finally, UBS Group dropped their price target on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. Six equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $241.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.